https://orcid.org/0000-0001-6000-8440
References
- Liu Z, Tang X, Liu Y, et al. HIV prevention and health poverty alleviation - liangshan prefecture, Sichuan Province, China, 2017-2020. Chin CDC Weekly. 2021 Nov 26;3(48):1031–8. doi: 10.46234/ccdcw2021.250
- Bandera A, Gori A, Clerici M, et al. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol. 2019 Oct;48:24–32.
- Mbisa JL, Ledesma J, Kirwan P, et al. Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. J Antimicrob Chemother. 2020 Nov 1;75(11):3311–3318. doi: 10.1093/jac/dkaa309
- Yang Z, Yang X, Deng X, et al. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020). Infection. 2021 Dec;49(6):1195–1202. doi: 10.1007/s15010-021-01668-9
- Casadella M, Santos JR, Noguera-Julian M, et al. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. J Antimicrob Chemother. 2020 Dec 1;75(12):3517–3524. doi: 10.1093/jac/dkaa349
- Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236–248. doi: 10.1038/nrd1660
- Chen Q, Cheng X, Wei D, et al. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of elvitegravir-resistance HIV-1 integrase. Interdiscip Sci. 2015 Mar;7(1):36–42. doi: 10.1007/s12539-014-0235-8
- Stekler JD, McKernan J, Milne R, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther. 2015;20(1):77–80. doi: 10.3851/IMP2780
- Ji H, Patterson A, Taylor T, et al. Prevalence of primary drug resistance against HIV-1 integrase inhibitors in Canada. J Acquir Immune Defic Syndr. 2018 May 1;78(1):e1–e3. doi: 10.1097/QAI.0000000000001649
- Antiretroviral Therapy Cohort C, May MT, Vehreschild J-J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349–e356. doi: 10.1016/S2352-3018(17)30066-8
- Huang Xiaotong SZ, Minghui A. Primary drug resistance to integrase inhibitors among newly diagnosed HIV infected patients in Shenyang city. Chin J Lab. 2019;37(10):5.
- Deng XM, Liu JF, Zhang ME. Mutations of primary integrase gene resistance of HIV/AIDS patients in Yunan province. J AIDS Clin Res. 2019;25(4):327–330+341.
- Yin YQ, Lu J, Zhou Y, et al. Drug resistance to HIV-1 integrase inhibitors among treatment-naive patients in Jiangsu, China. Biomed Environ Sci. 2021 May 20;34(5):400–403. doi: 10.3967/bes2021.053
- Upstream News. By the end of October 2021, Chongqing ranked sixth in China, in the number of people living with HIV (PLWH; 58,000), with 19,000 deaths related to AIDS . 2021.
- Group AaHCP. The Chinese guidelines for diagnosis and treatment of HIV/AIDS. Chin J AIDS STD. 2021;27(11):1182–1201.
- Yu F, Li Q, Wang L, et al. Drug resistance to HIV-1 integrase inhibitors among treatment-naive patients in Beijing, China. Pharmgenomics Pers Med. 2022;15:195–203. doi: 10.2147/PGPM.S345797